DK1113015T3 - Optisk aktive 3-[(2-piperazinyl-phenyl)methyl]-1-[4-(trifluormethyl)-phenyl]-2-pyrrolidinonforbindelser som 5-HT1D-receptor-selektive antagonister - Google Patents

Optisk aktive 3-[(2-piperazinyl-phenyl)methyl]-1-[4-(trifluormethyl)-phenyl]-2-pyrrolidinonforbindelser som 5-HT1D-receptor-selektive antagonister

Info

Publication number
DK1113015T3
DK1113015T3 DK00311130T DK00311130T DK1113015T3 DK 1113015 T3 DK1113015 T3 DK 1113015T3 DK 00311130 T DK00311130 T DK 00311130T DK 00311130 T DK00311130 T DK 00311130T DK 1113015 T3 DK1113015 T3 DK 1113015T3
Authority
DK
Denmark
Prior art keywords
phenyl
trifluoromethyl
optically active
piperazinyl
methyl
Prior art date
Application number
DK00311130T
Other languages
English (en)
Inventor
Mavis Diane Adam
Stephane Caron
Harry Ralph Howard Jr
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1113015T3 publication Critical patent/DK1113015T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00311130T 1999-12-29 2000-12-13 Optisk aktive 3-[(2-piperazinyl-phenyl)methyl]-1-[4-(trifluormethyl)-phenyl]-2-pyrrolidinonforbindelser som 5-HT1D-receptor-selektive antagonister DK1113015T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17343799P 1999-12-29 1999-12-29

Publications (1)

Publication Number Publication Date
DK1113015T3 true DK1113015T3 (da) 2004-12-13

Family

ID=22632024

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00311130T DK1113015T3 (da) 1999-12-29 2000-12-13 Optisk aktive 3-[(2-piperazinyl-phenyl)methyl]-1-[4-(trifluormethyl)-phenyl]-2-pyrrolidinonforbindelser som 5-HT1D-receptor-selektive antagonister

Country Status (9)

Country Link
US (2) US20010039280A1 (da)
EP (1) EP1113015B1 (da)
JP (1) JP3495708B2 (da)
AT (1) ATE276249T1 (da)
CA (1) CA2329576A1 (da)
DE (1) DE60013751T2 (da)
DK (1) DK1113015T3 (da)
ES (1) ES2225031T3 (da)
PT (1) PT1113015E (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222832A1 (en) * 2002-04-19 2003-11-03 Glaxo Group Limited Compounds having affinity at 5ht2c receptor and use thereof in therapy
CA2553291A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combination of .gamma.-aminobutyric acid modulators and 5-ht1b receptor antagonists
US8012969B2 (en) 2005-01-13 2011-09-06 Ge Healthcare Limited 11C-labeled benzyl-lactam compounds and their use as imaging agents
JPWO2006104280A1 (ja) * 2005-03-31 2008-09-11 武田薬品工業株式会社 糖尿病の予防・治療剤
WO2007012964A1 (en) * 2005-07-25 2007-02-01 Pfizer Products Inc. Preparation of alkylpiperazinylphenyl compounds by classical resolution
WO2007026224A2 (en) * 2005-08-31 2007-03-08 Pfizer Products Inc. 5-ht1b antagonist composition for depression, anxiety and cognition
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100211713B1 (ko) * 1990-06-01 1999-08-02 슈테펜 엘. 네스비트 (+)-알파-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올
FR2670491B1 (fr) * 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
FR2692264B1 (fr) * 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
BR9708581A (pt) * 1996-03-29 1999-08-03 Pfizer Derivados de benzil (IDENO)-lactama suas preparaçães e seus usos como (ANT) agonistas seletivas de recptores 5-HT 1A e/ou 5-HT 1D

Also Published As

Publication number Publication date
DE60013751T2 (de) 2005-09-29
JP3495708B2 (ja) 2004-02-09
EP1113015B1 (en) 2004-09-15
US20030083337A1 (en) 2003-05-01
CA2329576A1 (en) 2001-06-29
EP1113015A1 (en) 2001-07-04
ATE276249T1 (de) 2004-10-15
ES2225031T3 (es) 2005-03-16
US20010039280A1 (en) 2001-11-08
EP1113015A4 (en) 2001-03-23
PT1113015E (pt) 2004-12-31
JP2001187781A (ja) 2001-07-10
DE60013751D1 (de) 2004-10-21

Similar Documents

Publication Publication Date Title
JP2008110984A5 (da)
WO2005092307A3 (en) Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists
JO2371B1 (en) 4-phenyl-pyridine derivatives
ATE557026T1 (de) Vasopressin v1a antagonisten
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
CA2252898A1 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist
WO2006038006A3 (en) 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders
DK0392959T3 (da) Anvendelse af Sertindole til behandling af skizofreni
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
SE0302760D0 (sv) New compounds
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
MA27779A1 (fr) FORME CRISTALLINE D'AGONISTE DE RECEPTEUR β2 ADRENERGIQUE
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
SG164283A1 (en) New benzimidazole derivatives
PE20011114A1 (es) Decahidro-isoquinolinas
WO2007067875A3 (en) Pyridinyl sulfonamide modulators of chemokine receptors
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
WO2001023357A3 (en) Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists
DK1113015T3 (da) Optisk aktive 3-[(2-piperazinyl-phenyl)methyl]-1-[4-(trifluormethyl)-phenyl]-2-pyrrolidinonforbindelser som 5-HT1D-receptor-selektive antagonister
NO973652L (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreseptor-antagonist
MA26541A1 (fr) Nouvelles imidazolines, procede pour les preparer, compositions pharmaceutiques les contenant et leur utilisation dans le traitement de maladies soulagees par un traitement avec un antagoniste des recepteurs des prostaglandines
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
SE0002729D0 (sv) Novel compound form
RS51018B (sr) Farmaceutska kompozicija inhibitora pde4 ili inhibitora pde3/4 i antagoniste histamiinskih receptora